Answers are grounded in this paper and cite their sources.
Rationale: Emphysema is prevalent in smoke-exposed people living with HIV (PLWH). Matrix metalloproteinases (MMPs) are increased in bronchoalveolar lavage (BAL) fluid in PLWH with emphysema. Doxycycline is a U.S. Food and Drug Administration-approved MMP-9 inhibitor, in addition to its antimicrobial properties. Objectives: We aimed to test the safety and tolerability of doxycycline in PLWH. Methods: We created a single center, double-blind, randomized, placebo-controlled (2:1) pilot study of doxycycline 100mg orally twice daily in 27 PLWH who have chronic obstructive pulmonary disease and/or emphysema (NCT01744093). Measurements and Main Results: Our results revealed that doxycycline was safe and well-tolerated. There were robust serum and BAL fluid levels of doxycycline in individuals assigned to the doxycycline arm. Preliminary evidence of potential biologic effects of doxycycline in the lung included a reduction in BAL lung lymphocytes and a trend toward decreased MMP-9 activity. Conclusion: These data provide a rationale for a phase 2, 72-week randomized placebo-controlled trial of doxycycline to slow the progression of emphysema in PLWH (NCT05382208).
No takes yet. Share an insight, caveat, or question.
Kaner et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: